Daily Roundup

ALC.ASX GNP.ASX PME.ASX NHC.ASX GTK.ASX

Alcidion Group is bolstering its patient flow solutions with the acquisition of Kyra flow products from Telstra Health. The deal, worth an upfront $3.0 million with potential earn-outs of up to $1.0 million, is expected to be earnings accretive from day one. The Kyra suite—which includes Patient Flow Manager, Queue Manager, and IQ—will expand Alcidion's footprint across Australia, particularly in Queensland and Victoria. The transaction should close by the end of June 2026, with FY26 forecast revenue of $3.7 million and underlying EBITDA of approximately $1.1 million.

GenusPlus Group is having quite the week. The company upgraded its FY2026 earnings guidance, now expecting normalized EBITDA between A$96 million and A$100 million—a significant jump from the previous A$91 million forecast. That's growth of roughly 42-48% compared to FY2025's normalized EBITDA of $67.4 million, with A$2-3 million of the uplift coming from the Railtrain Holdings acquisition completed in April. But that's just the appetizer.

The real headline is GenusPlus's transformational acquisition of MPC Kinetic Holdings for up to A$400 million. This deal strategically diversifies the company into gas and water sectors, which are critical for Australia's energy security and transition. The transaction is expected to be highly earnings accretive and will complement GenusPlus's electrical capabilities with MPC Kinetic's expertise in pipelines and civil works. MPC Kinetic's existing management team will stay on board, with all staff remaining employed under GenusPlus. The deal should close on 1 July 2026, contingent on GenusPlus completing an equity raise of at least A$200 million. Speaking of which, GenusPlus has requested a trading halt on its securities pending announcement of the capital raising results, with the halt expected to remain in place until 20 May 2026.

Pro Medicus is making waves internationally with a A$90 million, 7-year contract with Boston-based Beth Israel Lahey Health. The deal covers implementation of the Visage 7 Enterprise Imaging Platform—including Visage 7 Viewer, Workflow, and Open Archive—all running on the cloud. Go-live is targeted for Q1 2027, and the contract operates on a transactional licensing model with upside potential.

New Hope Corporation delivered a solid quarterly update for the period ended 30 April 2026. The company achieved a 5.0% increase in Group ROM coal production to 4.3 million tonnes, while coal sales jumped 10.4% to 3.2 million tonnes. The average realized sales price came in at $140.7 per tonne, and Bengalla Mine achieved an impressive 12.4% reduction in FOB cash cost to $74.0 per sales tonne. Underlying EBITDA surged 21.7% to $130.1 million. On the capital front, New Hope issued $300 million in new senior unsecured convertible notes due 2032 and repurchased $293.3 million of its existing convertible notes due 2029. The company maintains a healthy cash balance of $571.6 million and expects increased demand in the coming quarter as the Northern Hemisphere moves into summer.

Gentrack Group had a busier day with multiple announcements. The company reported half-year results showing total revenue of $110.1 million, down slightly from $112.0 million in the prior period, though recurring revenue climbed 12% to $85.3 million. EBITDA excluding acquisition costs fell to $7.9 million from $13.0 million, while statutory NPAT dropped 29% to $5.1 million. The silver lining is a strong balance sheet with $73.2 million in cash reserves and no external debt. For FY26, Gentrack expects revenue between $229 million and $238 million, with recurring revenue growth exceeding 10%.

Gentrack also announced two acquisitions to strengthen its platform. The company acquired Factor, a New Zealand-based SaaS business serving the energy retail sector, for an enterprise value of NZ$24 million with potential earn-outs of NZ$10 million. Factor's platform enables utilities to price and manage commercial electricity contracts at scale, and the acquisition will enhance Gentrack's g2 energy retail platform. The deal is funded entirely from Gentrack's existing cash reserves and is expected to be accretive to FY28 earnings per share.